The FDA has issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites.
The letters cite violations including claims implying compounded products are the same as FDA-approved drugs, and advertising products under a telehealth firm’s name or trademark without clarifying the compounder. The FDA said compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing, according to a March 3 agency news release.
The action marks the second group of warning letters sent to telehealth firms since the agency launched a crackdown in September on misleading direct-to-consumer pharmaceutical advertisements. Over the past six months, the FDA said it has sent thousands of letters to pharmaceutical and telehealth firms — more than were sent over the entire preceding decade.
FDA Commissioner Marty Makary, MD, said in the news release the agency is monitoring misleading claims across media platforms and taking action.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
